TF2 Stock Overview
Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Takara Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥5.70 |
| 52 Week High | JP¥11.60 |
| 52 Week Low | JP¥5.40 |
| Beta | 0.22 |
| 1 Month Change | -2.56% |
| 3 Month Change | -22.97% |
| 1 Year Change | -50.00% |
| 3 Year Change | -72.86% |
| 5 Year Change | -70.76% |
| Change since IPO | 2,180.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| TF2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.8% | -5.1% | -2.0% |
| 1Y | -50.0% | -21.1% | -0.3% |
Return vs Industry: TF2 underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: TF2 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| TF2 volatility | |
|---|---|
| TF2 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TF2's share price has been volatile over the past 3 months.
Volatility Over Time: TF2's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,793 | Koichi Nakao | www.takara-bio.com |
Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing.
Takara Bio Inc. Fundamentals Summary
| TF2 fundamental statistics | |
|---|---|
| Market cap | €735.80m |
| Earnings (TTM) | €9.52m |
| Revenue (TTM) | €288.98m |
77.3x
P/E Ratio2.5x
P/S RatioIs TF2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TF2 income statement (TTM) | |
|---|---|
| Revenue | JP¥47.67b |
| Cost of Revenue | JP¥21.30b |
| Gross Profit | JP¥26.37b |
| Other Expenses | JP¥24.80b |
| Earnings | JP¥1.57b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | 13.05 |
| Gross Margin | 55.32% |
| Net Profit Margin | 3.30% |
| Debt/Equity Ratio | 0% |
How did TF2 perform over the long term?
See historical performance and comparison